The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Thromboxane–Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis
Open accessAbstract
Rationale: Although persistent fibroblast activation is a hallmark of idiopathic pulmonary fibrosis (IPF), mechanisms regulating persistent fibroblast activation in the lungs have not been fully elucidated. Objectives: On the basis of our observation that lung fibroblasts express TBXA2R (thromboxane–prostanoid receptor) during fibrosis, we investigated the role of TBXA2R signaling in fibrotic remodeling. Methods: We identified TBXA2R expression in lungs of patients with IPF and mice and studied primary mouse and human lung fibroblasts to determine the impact of TBXA2R signaling on fibroblast activation. We used TBXA2R-deficient mice and small-molecule inhibitors to investigate TBXA2R signaling in preclinical lung fibrosis models. Measurements and Main Results: TBXA2R expression was upregulated in fibroblasts in the lungs of patients with IPF and in mouse lungs during experimental lung fibrosis. Genetic deletion of TBXA2R, but not inhibition of thromboxane synthase, protected mice from bleomycin-induced lung fibrosis, thereby suggesting that an alternative ligand activates profibrotic TBXA2R signaling. In contrast to thromboxane, F2-isoprostanes, which are nonenzymatic products of arachidonic acid induced by reactive oxygen species, were persistently elevated during fibrosis. F2-isoprostanes induced TBXA2R signaling in fibroblasts and mediated a myofibroblast activation profile due, at least in part, to potentiation of TGF-β (transforming growth factor-β) signaling. In vivo treatment with the TBXA2R antagonist ifetroban reduced profibrotic signaling in the lungs, protected mice from lung fibrosis in three preclinical models (bleomycin, Hermansky-Pudlak mice, and radiation-induced fibrosis), and markedly enhanced fibrotic resolution after bleomycin treatment. Conclusions: TBXA2R links oxidative stress to fibroblast activation during lung fibrosis. TBXA2R antagonists could have utility in treating pulmonary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“OSM is a profibrotic glycoprotein – mice exposed to intranasal OSM demonstrated excessive collagen deposition in the lung, which was independent of TGF-β, IL-4, IL-3, and STAT, demonstrating the multiple pathways mediating pulmonary fibrosis [170–172].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [171]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Adams, T. S., Schupp, J. C., Poli, S., Ayaub, E. A., Neumark, N., Ahangari, F., Chu, S. G., Raby, B. A., DeIuliis, G., Januszyk, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba1983 · Cited by 1,420
Reyfman, P. A., Walter, J. M., Joshi, N., Anekalla, K. R., McQuattie-Pimentel, A. C., Chiu, S., Fernandez, R., Akbarpour, M., Chen, C.-I., Ren, Z., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2410oc · Cited by 1,203
Habermann, A. C., Gutierrez, A. J., Bui, L. T., Yahn, S. L., Winters, N. I., Calvi, C. L., Peter, L., Chung, M.-I., Taylor, C. J., Jetter, C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba1972 · Cited by 1,129
Self-citationMechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis
Liu, F., Lagares, D., Choi, K. M., Stopfer, L., Marinković, A., Vrbanac, V., Probst, C. K., Hiemer, S. E., Sisson, T. H., Horowitz, J. C., et al. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00300.2014 · Cited by 874
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury
Hecker, L., Vittal, R., Jones, T., Jagirdar, R., Luckhardt, T. R., Horowitz, J. C., Pennathur, S., Martinez, F. J., & Thannickal, V. J. (2009) · Nature Medicine · doi:10.1038/nm.2005 · Cited by 852
Isoprostanes: markers and mediators of oxidative stress
Montuschi, P., Barnes, P. J., & Roberts, L. J. (2004) · The FASEB Journal · doi:10.1096/fj.04-2330rev · Cited by 747
Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance
Hecker, L., Logsdon, N. J., Kurundkar, D., Kurundkar, A., Bernard, K., Hock, T., Meldrum, E., Sanders, Y. Y., & Thannickal, V. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008182 · Cited by 686
Oxidative stress and pulmonary fibrosis
Cheresh, P., Kim, S.-J., Tulasiram, S., & Kamp, D. W. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.021 · Cited by 530
Effects of a ginger extract on knee pain in patients with osteoarthritis
Altman, R. D., & Marcussen, K. C. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200111)44:11<2531::aid-art433>3.0.co;2-j · Cited by 507
Cited by
Oxidative Stress and Air Pollution: Its Impact on Chronic Respiratory Diseases
Sierra-Vargas, M. P., Montero‐Vargas, J. M., Debray-García, Y., Vizuet‐de‐Rueda, J. C., Loaeza-Román, A., & Teran, L. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010853 · Cited by 109
“TBXA2R links oxidative stress to fibroblast activation during lung fibrosis, and TBXA2R antagonists have been proposed for treating pulmonary fibrosis [97].”
BackgroundAnimal models of acute exacerbation of pulmonary fibrosis
Xu, Y., Zhang, M., Gu, H., Liu, M., Zhao, Y., Shi, Y., Wu, S., Jiang, C., Ye, X., Zhu, H., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02595-z · Cited by 43
“…in animal models and can cause varying degrees of lung fibrosis [70, 102, 103], such as asbestos (a single intratracheal administration), intratracheal instillation of particulate matter (PM 2.5) in mice [104], unilateral ureteral obstruction in rats [105], and chest radiation exposure [106, 107].”
BackgroundInfluentialPhysiological Effects of Ferroptosis on Organ Fibrosis
Du, X., Dong, R., Wu, Y., & Ni, B. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5295434 · Cited by 39
“In fibrosis-related diseases such as idiopathic pulmonary fibrosis (IPF) [69, 70], bronchial asthma [71], and chronic obstructive pulmonary disease (COPD) [72], the fibroblastto-myofibroblast transition, is one of the main mechanisms generating myofibroblasts in fibrotic lung tissue.”
BackgroundThe Role and Regulation of Thromboxane A2 Signaling in Cancer-Trojan Horses and Misdirection
Ashton, A. W., Zhang, Y., Cazzolli, R., & Honn, K. V. (2022) · Molecules · doi:10.3390/molecules27196234 · Cited by 34
“TP expression is upregulated in lung fibroblasts of mice and patients in response to damage and inflammation, as are isoprostanes [138].”
BackgroundEmerging therapies for the treatment of systemic sclerosis
Distler, J. H. W., Kuwana, M., Assassi, S., & Denton, C. P. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01294-x · Cited by 29
“Genetic deletion of Tbxa2r protected mice from bleomycin-induced lung fibrosis, suggesting the functional role of TPR signalling in fibrotic tissue remodelling 162 .”
Influential
Metadata
- Authors
- Suzuki, T., Kropski, J. A., Chen, J., Carrier, E. J., Chen, X., Sherrill, T. P., Winters, N. I., Camarata, J. E., Polosukhin, V. V., Han, W., Rathinasabapathy, A., Gutor, S., Gulleman, P., Sabusap, C., Banovich, N. E., Tanjore, H., Freeman, M. L., Tada, Y., Young, L. R., Gokey, J. J., Blackwell, T. S., & West, J. D.
- Affiliations
- University of Tsukuba (JP)
- Vanderbilt University (US)
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and
- Translational Genomics Research Institute (US)
- Vanderbilt University Medical Center (US)
- International University of Health and Welfare (JP)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- West, James D.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-09-01
- Volume
- 206
- Issue
- 5
- Pages
- 596-607
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC9716913
- OpenAlex
- W4283262510
- Cited by
- 24
- References
- 71
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 3
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL151016, R01HL135011, R01HL095797, P01HL108800, P01HL092870, R01HL145372, R01HL119503, K24HL143281, T32HL094296, K08HL130595)
- Doris Duke Charitable Foundation
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, thromboxane receptor, fibroblast activation, F2-isoprostanes, oxidative stress, myofibroblast activation, TGF-beta signaling, bleomycin-induced lung fibrosis, Hermansky-Pudlak syndrome, radiation-induced fibrosis, fibrotic remodeling
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Mice, Inbred C57BL, Prostaglandins, Thromboxanes, Transforming Growth Factor beta, Receptors, Thromboxane, F2-Isoprostanes, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thromboxane–Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.202106-1503oc
- The paper
- Suzuki, T., Kropski, J. A., Chen, J., Carrier, E. J., Chen, X., Sherrill, T. P., Winters, N. I., Camarata, J. E., Polosukhin, V. V., Han, W., Rathinasabapathy, A., Gutor, S., Gulleman, P., Sabusap, C., Banovich, N. E., Tanjore, H., Freeman, M. L., Tada, Y., Young, L. R., . . . West, J. D. (2022). Thromboxane–Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202106-1503oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.